PRODUCTS FOR INHALATION THERAPY

LORDE® HYAL – THE DIRECT WAY TO EXCRETE SPUMTUM!
- Acute nasopharyngeal diseases (nasopharyngitis, rhinosinusitis, etc.)
- Bronchitis
- Bronchiolitis
- Chronic obstructive pulmonary disease
- Perennial allergic rhinitis
- Seasonal allergic rhinitis

Natural sterile solution for improving of sputum or mucus excretion, reducing of swelling and improving of breathing.

**Ingredients:** 1 ml of solution contains 30.0 mg of sodium chloride and 1.0 mg of sodium hyaluronate.

**Free of additives and dyes! Allowed for application from the moment of birth.**

**How to use:** 1 container 2 times per day inhaled (or according to the scheme prescribed). If necessary, the frequency of inhalations can be increased up to 4 times per day.

NASDAQ® – CAREFUL CLEANSING OF THE NASAL MUCOUS MEMBRANE
- Daily hygiene of the nasal cavity
- Moisturizing of the mucous membrane
- Cleansing of the nasal mucous membrane
- NASISOFT is used in the schemes of complex treatment of acute and chronic diseases of the nasopharynx and paranasal sinuses (nasopharyngitis, rhinosinusitis, seasonal and/or perennial rhinitis, etc.).

Natural sterile solution for improving of nasal breathing.

**Ingredients:** 1 ml of solution contains 9.0 mg of sodium chloride and 1.0 mg of sodium hyaluronate.

**Free of additives and dyes! Allowed for application from the moment of birth.**

**How to use:** 1 container 2 times per day inhaled using a nasal cannula or mask (or according to the scheme prescribed). If necessary, the frequency of inhalations can be increased up to 4 times per day.

Inject into the nasal passages:
- children 0 to 7 years old - 1-2 drops in each nasal passage 1-3 times per day;
- 7 to 12 years old and adolescents 13 to 16 years old - 2 drops in each nasal passage 2-4 times per day;
- adults - 2-3 drops in each nasal passage 3-6 times per day.

OKISTAR HYAL 7 – IMPROVED MUCOLYTIC CARE
- 7% sodium chloride is recommended by international protocols for use in patients with cystic fibrosis (level of evidence B)4
- 7% sodium chloride in patients with cystic fibrosis: 5
  - Improves lung function
  - Reduces complications
  - Improves quality of life

Hypertonic solution of sodium chloride with hyaluronic acid is developed for patients with cystic fibrosis, bronchiolitis, bronchiectasis.

**Ingredients:** 1 ml of solution contains 70.0 mg of sodium chloride and 1.0 mg of sodium hyaluronate.

**Free of additives and dyes! Allowed for application from the moment of birth.**

**How to use:** 1 container 2 times per day inhaled (or according to the scheme prescribed). If necessary, the frequency of inhalations can be increased up to 4 times per day.

---

DIACO Biofarmaceutici S.R.L.  
| Via Flavia 124, 34147 Trieste, Italy  
www.diaco.it

This material is designed and suitable for medical professionals only and for distribution during specialized medical events.

DIACO Biofarmaceutici S.R.L. does not recommend using products for purposes other than those specified in the instructions. Please refer to the full text of the instruction for medical use before application the product.
FACTS ONLY

HYALURONIC ACID

IN URT DISEASES

In the study, Lee JH et al. described that 2 weeks use of 0.2% sodium hyaluronate gel was an effective treatment strategy in patients with recurrent aphthous ulcers, and Nolan A and colleagues received similar data in patients with Behçet’s disease. In Pilot study on the effects of high molecular weight sodium hyaluronate in the treatment of chronic pharyngitis (2015), Leone Carlo reported on the efficacy of sodium hyaluronate in patients with chronic pharyngitis compared to the control group. He noted: “The results show a significant improvement in symptoms and cytology...”

Palmieri B et al. were the first to evaluate the benefits of sodium hyaluronate in adults suffering from gastroesophageal reflux disease.

IN CHILDREN

Macchi et al. demonstrated that the addition of rebulized sodium hyaluronate to intranasal corticosteroid spray in patients with chronic respiratory syndrome (CRS) and nasal hayfever contributed to a rapid and significant improvement in nasal symptoms, endoscopic parameters, X-ray and saccharine purification tests compared to the control group. In order to minimize the symptoms and prevent the exacerbation in patients with CRS, Casale et al. used a periodic treatment with sodium hyaluronate after surgical intervention (10 days per month, 3 months during the winter period), which significantly improved the quality of life and reduced the number of complaints in patients compared to those treated only with saline solution.

ANTI-ADHESIVE PROPERTIES AND ABILITY TO PREVENT BIOFILM FORMATION

Almost two decades ago, Pavesio et al. were the first to describe the ability of hyaluronic acid to resist bacterial adhesion. Pavesio et al. were the first to describe the ability of hyaluronic acid to prevent the biofilm formation.

SHORT INFORMATION ON THE USE OF NASISOFT

PRODUCT: 1 ml of solution contains: sodium chloride - 30.0 mg; sodium hyaluronate - 1.0 mg. Indications: bronchitis, bronchiolitis, cystic fibrosis, bronchectasis and chronic obstructive pulmonary disease; acute and chronic diseases of the respiratory tract; complex upper respiratory tract (URT) compared to the use of saline solutions without hyaluronic acid:

- better dynamics of cytological, microbiological, endoscopic and clinical outcomes of treatment.
- significant decrease in the number of neutrophils (cytology).

Cassandro et al. demonstrated that 2 weeks use of 0.2% sodium hyaluronate gel was an effective treatment strategy in patients with recurrent aphthous ulcers, and Nolan A and colleagues received similar data in patients with Behçet’s disease. In Pilot study on the effects of high molecular weight sodium hyaluronate in the treatment of chronic pharyngitis (2015), Leone Carlo reported on the efficacy of sodium hyaluronate in patients with chronic pharyngitis compared to the control group. He noted: “The results show a significant improvement in symptoms and cytology...”

Palmieri B et al. were the first to evaluate the benefits of sodium hyaluronate in adults suffering from gastroesophageal reflux disease.

SHORT INFORMATION ON THE USE OF OKISTAR HYAL

PRODUCT: 1 ml of solution contains: sodium chloride - 70.0 mg; sodium hyaluronate - 10.0 mg. Indications: bronchitis, bronchiolitis, cystic fibrosis, bronchectasis and chronic obstructive pulmonary disease. Contraindication: High individual sensitivity to the drug components. Adverse reactions. In patients with individual intolerance to the components of the solution, adverse reactions are possible. In rare cases, hyperemia of the nasal mucous membrane, cough or bronchospasm may occur.